478375-40-5

Basic information

• Product Name: 3-BROMO-5-METHYL-BENZOIC ACID METHYL ESTER
• Synonyms: 3-BROMO-5-METHYL-BENZOIC ACID METHYL ESTER;Methyl 3-broMo-5-Methylbenzoate;Benzoic acid, 3-bromo-5-methyl-, methyl ester;3-bromo-5-methylbenzoate methyl
• CAS NO: 478375-40-5
• Molecular Formula: C₉H₉BrO₂
• Molecular Weight: 229.0706
• Mol File: 478375-40-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 271.8±20.0℃ (760 Torr)
• Flash Point: 118.2±21.8℃
• Appearance: /
• Density: 1.433±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-BROMO-5-METHYL-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-METHYL-BENZOIC ACID METHYL ESTER(478375-40-5)
• EPA Substance Registry System: 3-BROMO-5-METHYL-BENZOIC ACID METHYL ESTER(478375-40-5)

Safety Data

• Hazardous Substances Data: 478375-40-5(Hazardous Substances Data)

Usage

Chemical Properties

off-white powder

Upstream product

• 67-56-1 methanol 
• 58530-13-5 3-bromo-5-methyl-benzoic acid 
• 929626-17-5 methyl 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 632625-96-8 3-nitro-5-(2-oxopyrrolidin-1-yl)benzoic acid methyl ester 
• 877624-40-3 methyl 3-bromo-5-(bromomethyl)benzoate 
• 161796-10-7 3-bromo-5-(methoxycarbonyl)benzoic acid 
• 878741-84-5 methyl 3-bromo-5-(cyanomethyl)benzoate 
• 632625-97-9 3-amino-5-(2-oxo-pyrrolidin-1-yl)-benzoic acid methyl ester 
• 632625-98-0 3-{2-[5-bromo-2-(2,4-difluorobenzyloxy)phenyl]-5-methylpyrrol-1-yl}-5-(2-oxopyrrolidin-1-yl)benzoic acid methyl ester 
• 632623-69-9 3-{2-[5-bromo-2-(4-fluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-5-(2-oxo-pyrrolidin-1-yl)benzoic acid 

Relevant articles and documents

Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors

A series of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides was designed and synthesized as new tropomyosin receptor kinases (Trks) inhibitors by utilizing a structure-guided optimization strategy. One of the most potent compounds 9o suppressed TrkA/B/C with IC50 values of 2.65, 10.47 and 2.95 nM, respectively. The compound dose-dependently inhibited brain-derived neurotrophic factor (BDNF)-mediated TrkB activation and suppressed migration and invasion of SH-SY5Y-TrkB neuroblastoma cells expressing high level of TrkB. Inhibitor 9o also inhibited the proliferation of SH-SY5Y-TrkB cells with an IC50 value of 58 nM, which was comparable to that of an US FDA recently approved drug LOXO-101. Compound 9o may serve as a new lead compound for further anti-cancer drug discovery.

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Meta halogenation of 1,3-disubstituted arenes via iridium-catalyzed arene borylation

We report the meta halogenation of 1,3-disubstituted arenes to form 3,5-disubstituted aryl bromides and chlorides by using iridium-catalyzed arene borylation chemistry. Iridium-catalyzed borylation of arenes with B2pin2, followed by reaction of the boronic ester with copper(II) bromide or chloride converts arylboronic esters to the corresponding aryl halides. A variety of arenes containing alkoxy, alkyl, halogen, nitrile, ester, amide, and pivaloyl and TIPS-protected alcohols were converted to the corresponding 3,5-disubstituted aryl bromides and chlorides in yields ranging from 46% to 85%. In addition, 2,6-disubstituted and 3-substituted pyridines were converted to the 4-halo and 5-halopyridines, respectively. The utility of this methodology was demonstrated by the formal conversion of nicotine to Altinicline in three steps with an overall yield of 61% using meta bromination of nicotine as the first step. Copyright